Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR ...
Yahoo Finance

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small ...

ZEGFROVY ® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins WU-KONG28 is the first global randomized ...
Science Daily

MIT scientists strip cancer of its sugar shield

Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells more effectively. Their strategy targets a hidden “off switch” that tumors ...
Las Vegas Sun

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...

AI-powered atlas reveals new insights into tertiary lymphoid structures as prognostic and response biomarkers in cancer

In a study published in Science, researchers from The University of Texas MD Anderson Cancer Center have developed a spatial atlas of specialized immune structures, called tertiary lymphoid structures ...